Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/1468
Title: (-)-Epigallocatechin gallate derivatives for inhibiting proteasome
Authors: Chan, TH 
Lam, WH
Chow, LMC 
Dou, QP
Kuhn, DJ
Kazi, A
Keywords: Catechin
Anticancer agent
Issue Date: 9-Jun-2009
Source: US Patent 7,544,816 B2. Washington, DC: US Patent and Trademark Office, 2009. How to cite?
Abstract: (-)-EGCG, the most abundant catechin, was found to be chemopreventive and anticancer agent. However, (-)-EGCG has at least one limitation: it gives poor bioavailability. This invention provides compounds of generally formula 10, wherein R₁ is selected from the group of --H and C₁ to C[sub 6] acyl group; R₂, R₃, and R₄ are each independently selected from the group of --H, --OH, and C₁ to C[sub 6] acyloxyl group; and at least one of R₂, R₃, or R₄ is --H. The derivatives of (-)-EGCG that is at least as potent as (-)-EGCG. The carboxylate protected forms of (-)-EGCG and its derivatives are found to be more stable than the unprotected forms, which can be used as proteasome inhibitors to reduce tumor cell growth.
URI: http://hdl.handle.net/10397/1468
Rights: Assignee: The Hong Kong Polytechnic University.
Assignee: Wayne State University.
Assignee: University of South Florida.
Assignee: McGill University.
Appears in Collections:Patent

Files in This Item:
File Description SizeFormat 
us7544816b2.pdf1.26 MBAdobe PDFView/Open
Show full item record

Page view(s)

369
Last Week
0
Last month
Checked on Sep 17, 2017

Download(s)

234
Checked on Sep 17, 2017

Google ScholarTM

Check



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.